Abstract

BackgroundCardiovascular diseases (CVDs) are the leading cause of mortality in India. Residual risk exists in patients receiving optimal guideline-directed medical therapy. Possession of certain somatic mutations, at a variant allele frequency of ≥ 2% in peripheral blood, driving clonal expansion in the absence of cytopenias and dysplastic hematopoiesis is defined as clonal hematopoiesis of indeterminate potential (CHIP). Recently, it was found that carriers of CHIP had a higher risk to have coronary artery disease (CAD) and early-onset myocardial infarction. Association of CHIP with heart failure and valvular heart diseases is increasingly being considered. The common link that connects CHIP mutations and CVDs is inflammation leading to increased expression of cytokines and chemokines. We intended to do a systematic review about the association of CHIP mutations and CVD along with identifying specific CHIP mutations involved in increasing the risk of having CVDs. The main body of the abstractWe performed an extensive literature search in PubMed and Google Scholar databases. Out of 302 articles, we narrowed it down to 10 studies based on our pre-specified criteria. The methodology adopted for the identification of CHIP mutations in the selected studies included – whole-exome sequencing (n = 3), whole-genome analysis (n = 1), transcriptome profiling analysis (n = 1), whole-genome analysis (n = 1), and single-cell RNA-sequencing (n = 1). We found that the available literature suggested an association between CHIP and CVD. The most commonly described CHIP mutations in patients with CVD are DNMT3A, TET2, ASXL1, TP53, JAK2, and SF3B. We further analyzed the commonly mutated CHIP genes using bioinformatics tools. Protein function and interaction analysis were performed using the g: Profiler and GeneMANIA online tools. The results revealed significant bio grid interactions for molecular functions, biological processes, and biological pathways. Interaction analysis showed significant physical and co-expression interactions. Short conclusionWe conclude that there exists a significant association between CHIP mutations and CVD with DNMT3A, TET2, ASXL1, TP53, JAK2, and SF3B as the commonly implicated genes. The recognition of the link between CHIP and cardiovascular events will expand our understanding of residual risk and will open up new avenues of investigation and therapeutic modalities in the management of patients with CVD.

Highlights

  • Atherosclerotic cardiovascular diseases (ASCVD) remain the major cause for mortality and morbidity globally [3]

  • Short conclusion: We conclude that there exists a significant association between clonal hematopoiesis of indeterminate potential (CHIP) mutations and CVD with DNA Methyltransferase 3 Alpha (DNMT3A), Tet Methylcytosine Dioxygenase 2 (TET2), Additional Sex Combs Like Transcriptional Regulator 1 (ASXL1), TP53, Janus kinase 2 (JAK2), and Splicing factor 3B subunit 1 (SF3B) as the commonly implicated genes

  • The recognition of the link between CHIP and cardiovascular events will expand our understanding of residual risk and will open up new avenues of investigation and therapeutic modalities in the management of patients with CVD

Read more

Summary

Introduction

Atherosclerotic cardiovascular diseases (ASCVD) remain the major cause for mortality and morbidity globally [3]. As compared to western countries, CVD in India involve younger patients, many patients had STEMI They were less likely to receive evidencebased therapy and had higher mortality [14]. This shows there might be more than just conventional risk factors that may predispose south Asians for CVD. A recently concluded trial showed a major adverse cardiac event (MACE) in 10% of patients who had been targeted to have a LDL between 25 and 50 mg using pro-protein convertase subtilisin kexin-9 (PCSK9) inhibitors during the follow-up 2.2 years This highlights the importance of identifying residual risk for future MACE non-traditional and nonconventional risk factors for ASCVD. The hallmarks of CHIP are an absence of phenotypic variation in blood cells that implies hematological evidence; the presence of a somatic mutation that is associated with the hematologic condition, at a VAF of > 2%; and the lack of diagnostic symptoms that are associated with hematological cancer [1, 2]

Methods
Results
Discussion
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.